Hikma Pharmaceuticals Plc Board Committee Changes (4005E)
27 Febbraio 2020 - 05:35PM
UK Regulatory
TIDMHIK
RNS Number : 4005E
Hikma Pharmaceuticals Plc
27 February 2020
Hikma Pharmaceuticals PLC - Board Committee Changes
London, 27 February 2020 - Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ( Hikma ) Further to our announcement last year that
the Board was considering succession for the Senior Independent
Director role, we are pleased to announce that Pat Butler has
agreed to become the chair of the Nomination and Governance
Committee and Senior Independent Director. Pat's responsibilities
for chairing the Audit Committee will be handed over to a new
chair, who is being identified. Robert Pickering, the current
Senior Independent Director who has served for nine years, has
decided to retire from the Board following the implementation of
the changes. The effective date of the changes will be announced in
due course.
-- ENDS --
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, EVP Strategy and Global Affairs +44 (0)20 7399
2760
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
more than 40 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we're a global company with a local presence across the
United States (US), the Middle East and North Africa (MENA) and
Europe, and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,500 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFLFIRFLIDFII
(END) Dow Jones Newswires
February 27, 2020 11:35 ET (16:35 GMT)
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Hikma Pharmaceuticals (LSE:HIK)
Storico
Da Mar 2023 a Mar 2024